SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4589-4596. Prepublished online as a Blood First Edition Paper on February 16, 2006; DOI 10.1182/blood-2005-10-4169. This Article Full Text (PDF) All Versions of this Article: 2005-10-4169v1 107/12/4589    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dong, M. Articles by Blobe, G. C Search for Related Content PubMed PubMed Citation Articles by Dong, M. Articles by Blobe, G. C Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 20, 2005 Accepted February 3, 2006 Role of transforming growth factor- in hematological malignancies Mei Dong and Gerard C Blobe* Departments of Medicine and Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA * Corresponding author; email: blobe001{at}mc.duke.edu. The transforming growth factor- (TGF-) signaling pathway is an essential regulator of cellular processes including proliferation, differentiation, migration and cell survival. During hematopoiesis, the TGF- signaling pathway is a potent negative regulator of proliferation, while stimulating differentiation and apoptosis when appropriate. In hematological malignancies, including leukemias, myeloproliferative disorders, lymphomas and multiple myeloma, resistance to these homeostatic effects of TGF- develops. Mechanisms for this resistance include mutation or deletion of members of the TGF- signaling pathway and disruption of the pathway by oncoproteins. These alterations define a tumor suppressor role for the TGF- pathway in human hematological malignancies. On the other hand, elevated levels of TGF- can promote myelofibrosis and the pathogenesis of some hematological malignancies through their effects on the stroma and immune system. Advances in the TGF- signaling field should enable targeting of the TGF- signaling pathway for the treatment of hematological malignancies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Quintas-Cardama, H. M. Kantarjian, T. Manshouri, D. Thomas, J. Cortes, F. Ravandi, G. Garcia-Manero, A. Ferrajoli, C. Bueso-Ramos, and S. Verstovsek Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis J. Clin. Oncol., October 1, 2009; 27(28): 4760 - 4766. [Abstract] [Full Text] [PDF] M. S. Fernandes, E. M. Gomes, L. D. Butcher, R. Hernandez-Alcoceba, D. Chang, J. Kansopon, J. Newman, M. J. Stone, and A. W. Tong Growth Inhibition of Human Multiple Myeloma Cells by an Oncolytic Adenovirus Carrying the CD40 Ligand Transgene Clin. Cancer Res., August 1, 2009; 15(15): 4847 - 4856. [Abstract] [Full Text] [PDF] L. B. Baughn, M. Di Liberto, R. Niesvizky, H. J. Cho, D. Jayabalan, J. Lane, F. Liu, and S. Chen-Kiang CDK2 Phosphorylation of Smad2 Disrupts TGF-{beta} Transcriptional Regulation in Resistant Primary Bone Marrow Myeloma Cells J. Immunol., February 15, 2009; 182(4): 1810 - 1817. [Abstract] [Full Text] [PDF] Q. Zeng, S. Phukan, Y. Xu, M. Sadim, D. S. Rosman, M. Pennison, J. Liao, G.-Y. Yang, C.-C. Huang, L. Valle, et al. Tgfbr1 Haploinsufficiency Is a Potent Modifier of Colorectal Cancer Development Cancer Res., January 15, 2009; 69(2): 678 - 686. [Abstract] [Full Text] [PDF] T. Fujita, M. W. Epperly, H. Zou, J. S. Greenberger, and Y. Wan Regulation of the Anaphase-promoting Complex-Separase Cascade by Transforming Growth Factor-{beta} Modulates Mitotic Progression in Bone Marrow Stromal Cells Mol. Biol. Cell, December 1, 2008; 19(12): 5446 - 5455. [Abstract] [Full Text] [PDF] C. K. Cheng, L. Li, S. H. Cheng, K. M. Lau, N. P. H. Chan, R. S. M. Wong, M. M. K. Shing, C. K. Li, and M. H. L. Ng Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia Blood, October 15, 2008; 112(8): 3391 - 3402. [Abstract] [Full Text] [PDF] S. Romano, M. Mallardo, F. Chiurazzi, R. Bisogni, A. D'Angelillo, R. Liuzzi, G. Compare, and M. F. Romano The effect of FK506 on transforming growth factor {beta} signaling and apoptosis in chronic lymphocytic leukemia B cells Haematologica, July 1, 2008; 93(7): 1039 - 1048. [Abstract] [Full Text] [PDF] G. Fazio, C. Palmi, A. Rolink, A. Biondi, and G. Cazzaniga PAX5/TEL Acts as a Transcriptional Repressor Causing Down-modulation of CD19, Enhances Migration to CXCL12, and Confers Survival Advantage in pre-BI Cells Cancer Res., January 1, 2008; 68(1): 181 - 189. [Abstract] [Full Text] [PDF] T. Y. Zhang and R. A. Daynes Macrophages from 11beta-Hydroxysteroid Dehydrogenase Type 1-Deficient Mice Exhibit an Increased Sensitivity to Lipopolysaccharide Stimulation Due to TGF-beta-Mediated Up-Regulation of SHIP1 Expression J. Immunol., November 1, 2007; 179(9): 6325 - 6335. [Abstract] [Full Text] [PDF] D. Pan, T. Schomber, C. P. Kalberer, L. M. Terracciano, K. Hafen, W. Krenger, H. Hao-Shen, C. Deng, and R. C. Skoda Normal erythropoiesis but severe polyposis and bleeding anemia in Smad4-deficient mice Blood, October 15, 2007; 110(8): 3049 - 3055. [Abstract] [Full Text] [PDF] S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF] A. Fernandez-Lopez, E. M. Garrido-Martin, F. Sanz-Rodriguez, M. Pericacho, A. Rodriguez-Barbero, N. Eleno, J. M. Lopez-Novoa, A. Duwell, M. A. Vega, C. Bernabeu, et al. Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia Hum. Mol. Genet., July 1, 2007; 16(13): 1515 - 1533. [Abstract] [Full Text] [PDF] R. Bomben, M. Dal Bo, D. Capello, D. Benedetti, D. Marconi, A. Zucchetto, F. Forconi, R. Maffei, E. M. Ghia, L. Laurenti, et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study Blood, April 1, 2007; 109(7): 2989 - 2998. [Abstract] [Full Text] [PDF] B. J. Jenkins, A. W. Roberts, C. J. Greenhill, M. Najdovska, T. Lundgren-May, L. Robb, D. Grail, and M. Ernst Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis Blood, March 15, 2007; 109(6): 2380 - 2388. [Abstract] [Full Text] [PDF] R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020